Drug and Medication Industry: The Federico II University – Developmental Therapeutics Review – Q4 2010

• Publication date: December 2010

The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by G...

The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- The Federico II University - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of The Federico II University human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of The Federico II University with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the The Federico II University’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate The Federico II University’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of The Federico II University in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the The Federico II University’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with The Federico II University.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of The Federico II University and identify potential opportunities in those areas.

Global Therapy Industry

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
The Federico II University Snapshot 5
Key Information 5
Key Facts 5
The Federico II University – Research and Development Overview 6
Key Therapeutic Areas 6
The Federico II University – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Pipeline Products – Combination Treatment Modalities 11
The Federico II University – Pipeline Products Glance 12
The Federico II University – Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
The Federico II University Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
The Federico II University – Drug Profiles 14
Metformin 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
October reotide-LAR + Lanreotide Autogel 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Saizen 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Capecitabine + Gemcitabine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Dasatinib 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Epoetin alfa 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Epoetin Alfa for Friedreich's Ataxia 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Lithium 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Lithium carbonate 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
October reotide-LAR 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
The Federico II University – Pipeline Analysis 26
The Federico II University – Pipeline Products by Therapeutic Class 26
The Federico II University Pipeline Products By Target 28
The Federico II University – Pipeline Products by Route of Administration 30
The Federico II University – Pipeline Products by Molecule Type 32
The Federico II University – Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 35
Contact Us 35
Disclaimer 35List of Tables
The Federico II University – Pipeline by Therapy Area and Indication, 2010 8
The Federico II University – Pipeline by Stage of Development, 2010 9
The Federico II University – Monotherapy Products in Pipeline, 2010 10
The Federico II University – Combination Treatment Modalities in Pipeline, 2010 11
The Federico II University – Phase III, 2010 12
The Federico II University - Phase II, 2010 13
The Federico II University - Pipeline By Therapeutic Class, 2010 27
The Federico II University - Pipeline By Target, 2010 29
The Federico II University – Pipeline By Route of Administration, 2010 31
The Federico II University – Pipeline By Molecule Type, 2010 32

List of Figures
The Federico II University – Pipeline by Therapy Area and Indication, 2010 7
The Federico II University – Pipeline by Stage of Development, 2010 9
The Federico II University – Monotherapy Products in Pipeline, 2010 10
The Federico II University – Combination Treatment Modalities in Pipeline, 2010 11
The Federico II University – Pipeline By Therapeutic Class, 2010 26
The Federico II University - Pipeline By Target, 2010 28
The Federico II University – Pipeline By Route of Administration, 2010 30
The Federico II University – Pipeline By Molecule Type, 2010 32